Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems
From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same...
Gespeichert in:
Veröffentlicht in: | The European journal of health economics 2015-03, Vol.16 (2), p.113-118 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 118 |
---|---|
container_issue | 2 |
container_start_page | 113 |
container_title | The European journal of health economics |
container_volume | 16 |
creator | von der Schulenburg, J.-Matthias Graf Frank, Martin |
description | From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same time. Rare diseases collectively are frequent. That is why they are an extraordinary financial and organizational challenge for payers. The treatment of patients with rare diseases is either very costly and/or extremely difficult. For many of those diseases, no effective therapy exists. |
doi_str_mv | 10.1007/s10198-014-0639-8 |
format | Article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1658706412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>24773846</jstor_id><sourcerecordid>24773846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c538t-bb7ca7e0e20d017fc6b40abaf93c0c79ea939026a16333487bb1f5067497dfd13</originalsourceid><addsrcrecordid>eNp9kMtr3DAQh0VJaB7tH9BDiyCXXJyOJOuVWwh5FAKB0B6LkOVxdxevnWq8h_3vo63zKD0UBJKYb34zfIx9EnAmAOxXEiC8q0DUFRjlK_eOHQojXGUNiL2Xt_bugB0RrQCktFK9ZwdSK62l14fs50PMyJfEu4y_NzhMPA7t26cU0khTvz3neQe2S8JISDyWw9Mi9j0Ov5B3Y-YLjP204GnH0ZYmXNMHtt_FnvDj833Mflxffb-8re7ub75dXtxVSSs3VU1jU7QIKKEFYbtkmhpiEzuvEiTrMXrlQZoojFKqdrZpRKfB2NrbtmuFOmanc-5jHsviNIX1khL2fRxw3FAQRjsLphayoCf_oKtxk4ey3R8KtAddF0rMVMojUcYuPOblOuZtEBB27sPsPhT3Yec-uNLz5Tl506yxfe14kV0AOQNUSsVa_mv0f1I_z00rmsb8Flpbq1xt1BMFzZe8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1658059054</pqid></control><display><type>article</type><title>Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>JSTOR Archive Collection A-Z Listing</source><creator>von der Schulenburg, J.-Matthias Graf ; Frank, Martin</creator><creatorcontrib>von der Schulenburg, J.-Matthias Graf ; Frank, Martin</creatorcontrib><description>From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same time. Rare diseases collectively are frequent. That is why they are an extraordinary financial and organizational challenge for payers. The treatment of patients with rare diseases is either very costly and/or extremely difficult. For many of those diseases, no effective therapy exists.</description><identifier>ISSN: 1618-7598</identifier><identifier>EISSN: 1618-7601</identifier><identifier>DOI: 10.1007/s10198-014-0639-8</identifier><identifier>PMID: 25355295</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer</publisher><subject>Collaboration ; Cost analysis ; Delivery of Health Care - economics ; Delivery of Health Care - organization & administration ; Disease ; Drug Industry - economics ; Drugs ; Economic Policy ; EDITORIAL ; Enzymes ; Europe ; Genomes ; Health care ; Health care access ; Health care expenditures ; Health Care Management ; Health care policy ; Health Economics ; Health Planning - organization & administration ; Humans ; Life expectancy ; Medicine ; Medicine & Public Health ; Mutation ; Patient Preference ; Patients ; Pharmaceutical industry ; Pharmacoeconomics and Health Outcomes ; Physicians ; Public Finance ; Public Health ; Rare diseases ; Rare Diseases - economics ; Rare Diseases - epidemiology ; Reimbursement ; Statistical data</subject><ispartof>The European journal of health economics, 2015-03, Vol.16 (2), p.113-118</ispartof><rights>Springer-Verlag Berlin Heidelberg 2015</rights><rights>Springer-Verlag Berlin Heidelberg 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c538t-bb7ca7e0e20d017fc6b40abaf93c0c79ea939026a16333487bb1f5067497dfd13</citedby><cites>FETCH-LOGICAL-c538t-bb7ca7e0e20d017fc6b40abaf93c0c79ea939026a16333487bb1f5067497dfd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/24773846$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/24773846$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>315,781,785,804,27928,27929,41492,42561,51323,58021,58254</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25355295$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>von der Schulenburg, J.-Matthias Graf</creatorcontrib><creatorcontrib>Frank, Martin</creatorcontrib><title>Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems</title><title>The European journal of health economics</title><addtitle>Eur J Health Econ</addtitle><addtitle>Eur J Health Econ</addtitle><description>From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same time. Rare diseases collectively are frequent. That is why they are an extraordinary financial and organizational challenge for payers. The treatment of patients with rare diseases is either very costly and/or extremely difficult. For many of those diseases, no effective therapy exists.</description><subject>Collaboration</subject><subject>Cost analysis</subject><subject>Delivery of Health Care - economics</subject><subject>Delivery of Health Care - organization & administration</subject><subject>Disease</subject><subject>Drug Industry - economics</subject><subject>Drugs</subject><subject>Economic Policy</subject><subject>EDITORIAL</subject><subject>Enzymes</subject><subject>Europe</subject><subject>Genomes</subject><subject>Health care</subject><subject>Health care access</subject><subject>Health care expenditures</subject><subject>Health Care Management</subject><subject>Health care policy</subject><subject>Health Economics</subject><subject>Health Planning - organization & administration</subject><subject>Humans</subject><subject>Life expectancy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Patient Preference</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Physicians</subject><subject>Public Finance</subject><subject>Public Health</subject><subject>Rare diseases</subject><subject>Rare Diseases - economics</subject><subject>Rare Diseases - epidemiology</subject><subject>Reimbursement</subject><subject>Statistical data</subject><issn>1618-7598</issn><issn>1618-7601</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kMtr3DAQh0VJaB7tH9BDiyCXXJyOJOuVWwh5FAKB0B6LkOVxdxevnWq8h_3vo63zKD0UBJKYb34zfIx9EnAmAOxXEiC8q0DUFRjlK_eOHQojXGUNiL2Xt_bugB0RrQCktFK9ZwdSK62l14fs50PMyJfEu4y_NzhMPA7t26cU0khTvz3neQe2S8JISDyWw9Mi9j0Ov5B3Y-YLjP204GnH0ZYmXNMHtt_FnvDj833Mflxffb-8re7ub75dXtxVSSs3VU1jU7QIKKEFYbtkmhpiEzuvEiTrMXrlQZoojFKqdrZpRKfB2NrbtmuFOmanc-5jHsviNIX1khL2fRxw3FAQRjsLphayoCf_oKtxk4ey3R8KtAddF0rMVMojUcYuPOblOuZtEBB27sPsPhT3Yec-uNLz5Tl506yxfe14kV0AOQNUSsVa_mv0f1I_z00rmsb8Flpbq1xt1BMFzZe8</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>von der Schulenburg, J.-Matthias Graf</creator><creator>Frank, Martin</creator><general>Springer</general><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYYUZ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems</title><author>von der Schulenburg, J.-Matthias Graf ; Frank, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c538t-bb7ca7e0e20d017fc6b40abaf93c0c79ea939026a16333487bb1f5067497dfd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Collaboration</topic><topic>Cost analysis</topic><topic>Delivery of Health Care - economics</topic><topic>Delivery of Health Care - organization & administration</topic><topic>Disease</topic><topic>Drug Industry - economics</topic><topic>Drugs</topic><topic>Economic Policy</topic><topic>EDITORIAL</topic><topic>Enzymes</topic><topic>Europe</topic><topic>Genomes</topic><topic>Health care</topic><topic>Health care access</topic><topic>Health care expenditures</topic><topic>Health Care Management</topic><topic>Health care policy</topic><topic>Health Economics</topic><topic>Health Planning - organization & administration</topic><topic>Humans</topic><topic>Life expectancy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Patient Preference</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Physicians</topic><topic>Public Finance</topic><topic>Public Health</topic><topic>Rare diseases</topic><topic>Rare Diseases - economics</topic><topic>Rare Diseases - epidemiology</topic><topic>Reimbursement</topic><topic>Statistical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>von der Schulenburg, J.-Matthias Graf</creatorcontrib><creatorcontrib>Frank, Martin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Access via ABI/INFORM (ProQuest)</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ABI/INFORM Collection China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of health economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>von der Schulenburg, J.-Matthias Graf</au><au>Frank, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems</atitle><jtitle>The European journal of health economics</jtitle><stitle>Eur J Health Econ</stitle><addtitle>Eur J Health Econ</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>16</volume><issue>2</issue><spage>113</spage><epage>118</epage><pages>113-118</pages><issn>1618-7598</issn><eissn>1618-7601</eissn><abstract>From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same time. Rare diseases collectively are frequent. That is why they are an extraordinary financial and organizational challenge for payers. The treatment of patients with rare diseases is either very costly and/or extremely difficult. For many of those diseases, no effective therapy exists.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer</pub><pmid>25355295</pmid><doi>10.1007/s10198-014-0639-8</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1618-7598 |
ispartof | The European journal of health economics, 2015-03, Vol.16 (2), p.113-118 |
issn | 1618-7598 1618-7601 |
language | eng |
recordid | cdi_proquest_miscellaneous_1658706412 |
source | MEDLINE; SpringerNature Journals; JSTOR Archive Collection A-Z Listing |
subjects | Collaboration Cost analysis Delivery of Health Care - economics Delivery of Health Care - organization & administration Disease Drug Industry - economics Drugs Economic Policy EDITORIAL Enzymes Europe Genomes Health care Health care access Health care expenditures Health Care Management Health care policy Health Economics Health Planning - organization & administration Humans Life expectancy Medicine Medicine & Public Health Mutation Patient Preference Patients Pharmaceutical industry Pharmacoeconomics and Health Outcomes Physicians Public Finance Public Health Rare diseases Rare Diseases - economics Rare Diseases - epidemiology Reimbursement Statistical data |
title | Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T17%3A40%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rare%20is%20frequent%20and%20frequent%20is%20costly:%20rare%20diseases%20as%20a%20challenge%20for%20health%20care%20systems&rft.jtitle=The%20European%20journal%20of%20health%20economics&rft.au=von%20der%20Schulenburg,%20J.-Matthias%20Graf&rft.date=2015-03-01&rft.volume=16&rft.issue=2&rft.spage=113&rft.epage=118&rft.pages=113-118&rft.issn=1618-7598&rft.eissn=1618-7601&rft_id=info:doi/10.1007/s10198-014-0639-8&rft_dat=%3Cjstor_proqu%3E24773846%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1658059054&rft_id=info:pmid/25355295&rft_jstor_id=24773846&rfr_iscdi=true |